- Home
- IINN vs APRE Comparison
IINN vs APRE Comparison
Compare IINN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IINN
- APRE
- Stock Information
- Founded
- IINN 2018
- APRE 2006
- Country
- IINN Israel
- APRE United States
- Employees
- IINN N/A
- APRE N/A
- Industry
- IINN Medical/Dental Instruments
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IINN Health Care
- APRE Health Care
- Exchange
- IINN Nasdaq
- APRE Nasdaq
- Market Cap
- IINN 15.9M
- APRE 13.5M
- IPO Year
- IINN 2021
- APRE 2019
- Fundamental
- Price
- IINN $0.60
- APRE $1.50
- Analyst Decision
- IINN
- APRE Strong Buy
- Analyst Count
- IINN 0
- APRE 2
- Target Price
- IINN N/A
- APRE $15.50
- AVG Volume (30 Days)
- IINN 389.2K
- APRE 29.2K
- Earning Date
- IINN 04-29-2025
- APRE 05-13-2025
- Dividend Yield
- IINN N/A
- APRE N/A
- EPS Growth
- IINN N/A
- APRE N/A
- EPS
- IINN N/A
- APRE N/A
- Revenue
- IINN N/A
- APRE $1,502,581.00
- Revenue This Year
- IINN N/A
- APRE N/A
- Revenue Next Year
- IINN N/A
- APRE N/A
- P/E Ratio
- IINN N/A
- APRE N/A
- Revenue Growth
- IINN N/A
- APRE 157.63
- 52 Week Low
- IINN $0.54
- APRE $1.41
- 52 Week High
- IINN $2.45
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- IINN 39.40
- APRE 27.07
- Support Level
- IINN $0.53
- APRE $1.41
- Resistance Level
- IINN $0.70
- APRE $1.59
- Average True Range (ATR)
- IINN 0.07
- APRE 0.11
- MACD
- IINN 0.00
- APRE 0.02
- Stochastic Oscillator
- IINN 43.18
- APRE 18.60
About IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.